1. Home
  2. CYTK vs AAPG Comparison

CYTK vs AAPG Comparison

Compare CYTK & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • AAPG
  • Stock Information
  • Founded
  • CYTK 1997
  • AAPG 2009
  • Country
  • CYTK United States
  • AAPG China
  • Employees
  • CYTK N/A
  • AAPG N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • AAPG Biotechnology: Pharmaceutical Preparations
  • Sector
  • CYTK Health Care
  • AAPG Health Care
  • Exchange
  • CYTK Nasdaq
  • AAPG Nasdaq
  • Market Cap
  • CYTK 4.4B
  • AAPG 3.6B
  • IPO Year
  • CYTK 2004
  • AAPG 2025
  • Fundamental
  • Price
  • CYTK $38.62
  • AAPG $44.70
  • Analyst Decision
  • CYTK Buy
  • AAPG Buy
  • Analyst Count
  • CYTK 13
  • AAPG 1
  • Target Price
  • CYTK $71.58
  • AAPG N/A
  • AVG Volume (30 Days)
  • CYTK 1.4M
  • AAPG 7.0K
  • Earning Date
  • CYTK 08-07-2025
  • AAPG 08-20-2025
  • Dividend Yield
  • CYTK N/A
  • AAPG N/A
  • EPS Growth
  • CYTK N/A
  • AAPG N/A
  • EPS
  • CYTK N/A
  • AAPG N/A
  • Revenue
  • CYTK $85,738,000.00
  • AAPG $134,352,180.00
  • Revenue This Year
  • CYTK $27.08
  • AAPG N/A
  • Revenue Next Year
  • CYTK $652.09
  • AAPG $404.41
  • P/E Ratio
  • CYTK N/A
  • AAPG N/A
  • Revenue Growth
  • CYTK 2635.74
  • AAPG 341.77
  • 52 Week Low
  • CYTK $29.31
  • AAPG $16.50
  • 52 Week High
  • CYTK $59.39
  • AAPG $43.58
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 60.89
  • AAPG N/A
  • Support Level
  • CYTK $32.89
  • AAPG N/A
  • Resistance Level
  • CYTK $36.79
  • AAPG N/A
  • Average True Range (ATR)
  • CYTK 1.73
  • AAPG 0.00
  • MACD
  • CYTK 0.15
  • AAPG 0.00
  • Stochastic Oscillator
  • CYTK 91.77
  • AAPG 0.00

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About AAPG Ascentage Pharma Group International American Depository Shares

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

Share on Social Networks: